

Combined use of Armourbite and MLS® in temporomandibular disorders, craniofacial pain and neuromuscular dysbalance.

J. Rosswag¹ and U. Janke²

¹ Dres. Susanna Rosswag und Joachim Rosswag Hauptstr. Mannheim (Germany)

² Dr. Janke & Partner, Rodigallee 250, Hamburg (Germany)

ABSTRACT

Temporomandibular disorder (TMD) is a nonspecific diagnosis that includes a group of conditions involving the muscles of mastication and/or the temporomandibular joint (TMJ). TMD comprises a wide range of clinical symptoms, such as headache, facial and jaw pain, neck pain or movement limitation, etc. and severely impact on patient quality of life.

The incidence of the TMD in the general population is widespread and many people suffer to a greater or lesser degree from these disorders.

Current conservative gold standard treatment is represented by occlusal splints, but recently other therapeutic approaches are being used, among which laser therapy is giving interesting results. The aim of this study is to report on four cases in which the combination of MLS® laser treatment and the Armourbite splint was used to relief TMD symptoms. In order to provide some early comments on the comparison with the results obtained

with splint alone, 2 patients with similar characteristics and treated only with Armourbite have been included in this report as well.

In the studied patients, the MLS® laser therapy together with Armourbite splint represented an effective and fast treatment for TMD and in most cases the treatment was able of reestablishing the neuromuscular functions. Clinical studies are needed to confirm these preliminary observations and determine the most appropriate treatment parameters.

INTRODUCTION

The temporomandibular disorders (TMD) represent a range of clinical disorders involving the masticatory muscles, the temporomandibular joint and associated structures. Symptoms associated to TMD include: headaches; facial pain; jaw pain; sore, chipped, broken, or worn teeth, clicking or popping in the jaw, and limited jaw movement. In addition to pain symptoms, signs are frequently found joint sounds such as clicks or crackle and

limitation or deviation of mandibular opening. Some patients may experience all of the reported symptoms, while other will report only a few of those problems. The area of the face where the temporomandibular joint (TMJ) is located is a complex of bones, including the teeth, muscles, and nerves. Because of this, TMJ conditions affect many areas of the body, from the top of the head in migraine-like headaches to numbness or tingling in the arms and pain in the neck or shoulders. Data released by the American Academy of Orofacial Pain (AAOP) estimate that 75% of the population in the United States has presented signs and / or symptoms of TMD. These conditions are present in the very young population, increase with age to eventually decrease after age 50. The highest prevalence in the population is between 20 and 40 years of age. Globally, epidemiological studies have shown that approximately 10% of the population is affected, and 30-year-old women are the population segment most likely to be affected by TMD [1, 2].

It is known widely in the literature that, in most of the cases, TMD are due to a multifactorial etiology and the competition of multiple risk factors. The multifactorial etiology of the disorder requires a multidisciplinary treatment approach with a team that is responsible for the management of patients with problems of the stomatognathic system. Among the factors that can lead to TMD, the main one are trauma (i.e. car accident, sport injury), improper occlusion, joint inflammation, grinding or clenching of teeth, neuromuscular imbalance, diseases such as rheumatoid arthritis or degenerative osteoarthritis and sleep disorders.

The variety of disorders collected under the name of TMD makes diagnosis and treatment challenging. An accurate diagnosis is critical for successful treatment. Real-time objective physiologic data such as electromyography represent a useful

tool to support the dentist in providing the appropriate diagnosis as gives details information on craniomandibular alignment.

The therapy of the TMD is essentially based on conservative approaches and reversible, including counseling and the realization of occlusal splints constitute the reference standard, together with any drug therapy support. Splints are designed to fit over the teeth. They prevent the upper and lower teeth from coming together, based on the fact that the role of occlusion in the etiology of TMD has been widely documented in the dental literature [3].

Armourbite is a splint designed with the aim of creating an optimal spacing of the jaw by placing space between molars, preventing teeth from clenching. The specific design of Armourbite allows rotation of the lower jaw down and forward to help relieve pressure on the TMJ.

Recently, some studies have been addressing the use of alternative treatments, such as transcutaneous electrical nerve stimulation (TENS), ultrasound, trigger point injections and acupuncture. Laser therapy has also been considered for the treatment of TMD [4-6], based on the fact that its main effects, such as healing promotion, analgesic and anti-inflammatory effects, can play an important role in reducing signs and symptoms associated with TMD.

Given the multifactorial origin of TMD, the ideal treatment should include synergic strategies, targeting the different aspects of the condition in order to provide the patient with the most successful treatment.

In this light, the objective of this study was to report the preliminary experience on a random sample of 4 patients in which the combination of MLS® laser treatment and the Armourbite splint was used to relief TMD symptoms. In order to provide some early comments on the comparison with

the results obtained with splint alone, 2 patients with similar characteristics and treated only with Armourbite have been included in this report.

In order to evaluate appropriately the patient neuromuscular dysbalance, the electromyograph BTS TMJOINT was used.

MATERIALS AND METHODS

A group of patients coming from Dr Janke's and Dr Rosswag's practice have considered in this report. The material and methods applied had the following common aspects.

The inclusion criteria were: age ≥ 18 and < 75 years, presence of a retained TMJ opening, presence of parafunctions (clenching and bruxism), cervical spondylosis, neuromuscular dysbalance of the elevator muscles of the jaw (masseter and temporalis) evaluated with BTS TMJoint (BTS Bioengineering, Italy).

Patients wearing pacemakers, pregnant, subjects with severe comorbidities (such as hypertension, diabetes mellitus, cardiac rhythm), subjects with severe respiratory disease (COPD), outcomes of major traumatic diseases, subjects with chronic encephalopathy and cerebral disorders (i.e. Parkinson's disease, epilepsy) and severe postural conditions (such as congenital torticollis, asymmetry of the lower limbs) were excluded from the study.

At the first visit, clinical evaluation was performed, myofascial pain type was indicated (i.e. masseter/temporal muscle hypertonia, cervicgia, trapezius muscle hypertonia, sternocleidomastoid muscle hypertonia, TMJ pain or others), trigger points and irradiation areas were recorded by the dentist and the presence of edema, cervical arthrosis, muscle contracture, wound, trigger points, bruxism/clenching and/or other specific conditions was reported. Additionally, the patient was asked to estimate the number of pain events during the day and during

the week.

At the same visit, electromyograph (BTS TMJoint, BTS Bioengineering, Italy) was used to provide a gnathological examination of dental occlusion by recording electromyographic activity of the masseters and temporalis (left and right).

At each therapy session, the following assessments were performed:

- pain evaluation using the VAS scale (pre and post therapy)
- muscle contracture
- cervical spine range of motion (left and right)

Additionally, reactions, side effects and further notes were recorded.

The Armourbite group patients were treated with splint only (Armourbite Mouthpiece, BiteTech, UK).

The Armourbite and MLS® group received MLS® Laser Therapy (Mphi D, ASA S.r.l., Italy). MLS® laser is a class IV NIR laser with two synchronized sources (laser diodes). These emit at different wavelengths, peak power and emission mode. The first one is a pulsed 905 nm laser diode with 25 W peak optical power. The pulse frequency may be varied in the range 1-2000 Hz, thus varying the average power delivered to the tissue. The second laser diode (808 nm) may operate in continuous (power 1.1 W) or pulsed mode (repetition rate 1-2000 Hz, 550mW mean optical power, with a 50% duty ratio independently of the repetition rate). The two laser beams are emitted synchronously and the propagation axes are coincident. The treatment was carried out by treating the patient with a holistic approach consisting in the treatment of muscle contracture and trigger points. The following operating parameters were applied according to the static and dynamic protocol. Static protocol for TMJ treatment includes treatment of the condyle and masseter area (Energy delivered= 47J) and also of trigger points on the sternocleidomastoid (SCM), if present (Energy delivered=3J

for point). Static protocol for shoulder and cervical pain includes treatment over paravertebral area from C3 to C7 bilaterally and the upper trapezius (Energy delivered= 41J). If present, trigger points on the upper trapezius area and on SCM area are treated (Energy delivered=3J for point).

During dynamic protocols, MLS® treatment is performed in scanning mode on areas where muscles are in motion. TMJ treatment is performed during depression/elevation movements and mandibular lateral excursion. Cervical area treatment involves the application during cervico-cranial rotation, and extension/flexion and lateral flexion movements. For dynamic trigger point treatment, the patient has to actively extend the belly of the muscle, with the help on the operator, and in this condition the supraspinatus muscle trigger points must be specifically treated.

RESULTS

Six individuals have been included in this case report. Two patients received Armourbite treatment and four patients received Armourbite together with MLS® treatment.

Case #1 - Patient treated with Armourbite

Female patient, 57 years old presenting headache and back, neck and shoulder pain and reported sleeping problems. At clinical evaluation, hip height and leg length differences were observed. Myofascial painful points were located at the masseter/temporal and trapezius muscles.

Muscle contracture, trigger points and bruxism/clenching were also present. The patient reported pain events during the time with a duration of less than 5 hours and a weekly occurrence of pain events between 3 and 5 times.

The patient received Armourbite treatment and was followed up for 5

weeks. In this period, VAS score improved of 6 points, from 8 to 2.

Muscle contracture was also evaluated on a 10-point scale and changed from 8 to 2 in the observation period.

Cervical spine range of motion improved from 50° on the right side and 50° on the left side at the first assessment to 90° on the right side and 90° on the left side after the observation period. Back pain was reduced of 50% at the end of the treatment.

Headache, sleeping and hip/leg discrepancy issues were solved after the treatment with Armourbite.

Case #2 - Patient treated with Armourbite

Male patient, 36 years old presenting neck problems. Myofascial painful points were located at the trapezius muscle, on the left and right side. The patient reported pain events during the time with a duration between 5 and 10 hours/day and a weekly occurrence of pain events between 1 and 3 times.

The patient received Armourbite treatment and was observed for 4 days. In this period, VAS score related to neck pain immediately improved of 7 points, from 8 to 1.

Case #3 - Patient treated with Armourbite+MLS®

Female patient, 25 years old presenting neck problems. Myofascial painful points were located at the left side of trapezius muscle. Trigger points were present. The patient reported pain events during the time with a duration between 5 and 10 hours/day and a weekly occurrence of pain events between 3 and 5 times.

The patient received Armourbite + MLS® treatment for 3 consecutive days. MLS® treatment was performed using the scanning mode on the upper trapezius with the following parameters: Frequency 700 Hz; Intensity 50%; Time 1' 30" per side. Dose is 1,24J/cm².

The VAS score immediately improved of 7 points from 8 to 1. Trigger point pain also improved from 8 to 3 on the third day.

Case #4 - Patient treated with Armourbite+MLS®

Female patient, 56 years old presenting Atlas displacement, painful left TMJ side, neck pain and limited range of motion. Myofascial painful points were located at masseter/temporal, sternocleidomastoid and trapezius muscle, additionally, cervicgia was reported. Muscle contracture, trigger points and bruxism/clenching were also present.

The patient reported more than 10 hours/day of pain events and a weekly occurrence of pain events of 5 or more days.

The patient received Armourbite + MLS® treatment and was followed up for 3 months.

The treatment involved a first phase with the use of Armourbite Mouthguard alone, the second phase involved the MLS® treatment which comprised 5 sessions over 3 months: from 1 to 4, using the static program, while session #5 was carried out with the dynamic protocol.

The static and dynamic programs involve the use of the following parameters:

- Frequency:350 Hz; Intensity: 50%; Time: 3';
- Frequency:700 Hz; Intensity: 50%; Time: 2' 30";
- For Trigger points: Frequency:10 Hz; Intensity: 25%; Time:25";

Energy dose for each trigger point is 1 J/cm²
Energy dose for each area for static program is in the range 0.8 – 2,5 J/cm²
Energy dose for each area for dynamic program is <0.5 J/cm²

The VAS score immediately improved of 7 points from 7 to complete and stable pain elimination. Full range of motion was recovered at the end of the treatment sessions.

Case #5 – Patient treated with Armourbite+MLS®

Male patient, 45 years old presenting very limited neck range of motion. The patient reported to be able to sustain only up to 30 min in the sitting position, as after this time both leg numbness occurred. Myofascial painful points were located on the right side at masseter/temporal, TMJ, sternocleidomastoid and trapezius muscle, additionally, cervicalgia was reported. Muscle contracture, trigger points and bruxism/clenching were also present.

The patient reported more than 10 hours/day of pain events and a weekly occurrence of pain events of 5 or more days.

The patient received Armourbite + MLS® treatment and was followed up for 4 weeks.

The treatment involved a first phase with the use of Armourbite Mouthguard alone, the second phase involved the MLS® treatment which comprised 5 sessions over 1 week: from 1 to 4, using the static program, while session #5 was carried out with the dynamic protocol.

The static and dynamic programs involve the use of the following parameters:

- Frequency: 350 Hz; Intensity: 50%; Time: 3';
- Frequency: 700 Hz; Intensity: 50%; Time: 2' 30'';
- For Trigger points: Frequency: 10 Hz; Intensity: 25%; Time: 25'';

Energy dose for each trigger point is 1 J/cm²
Energy dose for each area for static program is in the range 0.8 – 2,5 J /cm²
Energy dose for each area for dynamic program is <0.5 J/cm²

The VAS score improved of 9 points from 10 to 1.

Range of motion improved of 50% after the first phase with Armourbite and full range of motion was recovered after the second phase with MLS® therapy.

The problem related to the sitting position dramatically improved and the

patient reported the possibility of sitting for more than 5 hours without lower limb numbness occurrence.

Case #6 – Patient treated with Armourbite+MLS®

Female patient, 26 years old reporting pain after sleeping. Myofascial painful points were located at the left side of masseter/temporal muscle. Trigger points and bruxism/clenching were present. The patient reported between 1 and 5 hours of pain events during the day and a weekly occurrence of pain events between 1 and 3 times.

The patient received Armourbite + MLS® treatment and was followed up for 9 days. The MLS® treatment involved 4 sessions performed with the static program dedicated to the masseter area, using the following parameters: Frequency 350 Hz; Intensity 50%; Time 30'. Dose is 0.8 J/cm². The VAS score immediately improved of 6 points from 7 to 1.

DISCUSSION

As a general comment, both the treatments used (splint and laser therapy) were well tolerated by the patients and no adverse effects have been reported.

Armourbite is a splint designed to re-establish the neuromuscular balance in the masticatory system. The impact of the Armourbite treatment can both treat local painful symptoms, and also deeply affect quality of life, such as eliminating headache and sleeping disorders. This is confirmed by the two cases, #1 and #2, which received Armourbite treatment alone.

Laser application is effective in reducing TMD symptoms, especially pain [7], and has influence over masticatory efficiency [8].

Therefore, the combination of Armourbite splint and MLS® laser therapy seems to be a promising and practical approach to address the complex TMD picture.

The combined therapeutic protocol

including Armourbite and MLS®, applied in 4 of the reported cases, was easy to follow, very effective and was able to provide results in a limited number of sessions. In particular, it was evidenced that some selected cases can obtain beneficial outcome even in just 3 days of treatment, as happened for case #3.

Therefore, MLS® appeared to be a treatment able to maximize the positive effects of Armourbite: the joint effect of the two strategies is exemplified in case #5, where 50% improvement in range of motion was obtained with the use of Armourbite and then the addition of MLS® treatment allowed for a full range of motion restoration.

In fact, MLS® laser therapy can reduce inflammation, decrease muscle contracture and improve muscle function by inducing the synthesis and/or modulation of proteins involved in the regulation of inflammasome activity, anabolic processes, contraction/relaxation processes [9].

In order to make the most from the treatment of TMD with MLS® laser therapy, a global approach is recommended. This involves not only the local painful point treatment, but includes the all muscle groups and trigger points that are involved in the pathology, directly or indirectly. To maximize the effect of the treatment, static and dynamic procedures have been defined. Generally, the first treatment phase involves the static treatment and the dynamic procedure completes the therapy in the latter sessions i.e. case #4 and case #5. The static treatment aims at decontracting, reducing inflammation and pain. The dynamic protocol adds to these effects the proprioceptive and joint recovery. The combination of the two is especially indicated in high complexity situations, where several painful areas can be identified and the pain symptoms are also associated to other problems, for examples limited ROM and bruxism/clenching (case #4) and also limb

problems (case #5).

The reported cases demonstrate the positive outcome in the TMD treatment when the combination of Armourbite splint and MLS® therapy is used, nevertheless, more clinical information are needed to clarify the mechanism of action of this protocol and confirm the clinical significance. A randomized controlled study would be the ideal clinical method to further study the combination of these two approaches in the treatment of TMD and related issues.


Key features for reliable studies are the reporting of allocation, blinding, sequence generation, withdrawals, intention-to-treat analysis, and any other potential source of bias in the study. In addition, there should be use of well-validated standardized outcomes so that the RCTs could be compared with other similar trials [10].


CONCLUSION

In the reported cases, the MLS® laser therapy together with Armourbite splint represented a very effective, fast, predictable and successful treatment for TMD and in most cases the treatment was able of reestablishing the neuromuscular functions exceeding the clinical expectations. Additional clinical studies are required to confirm this preliminary experience in the combination of MLS® and Armourbite, to optimize treatment modalities and to identify the patients that can get the most by this therapeutic combination.

BIBLIOGRAPHY

1. Magnusson T., Egermark I., Carlsson G.E.. Treatment received, treatment demand, and treatment need for temporomandibular disorders in 35-year-old subjects. *Cranio* 2002;20:11-7.
2. Al-Jundi M.A., John M.T., Setz J.M., et al. Meta-analysis of treatment need for temporomandibular disorders in adult nonpatients. *J Orofac Pain* 2008;22:97-107.
3. Čelić R., Kraljević K., Kraljević S., Badel T., Pandurić J. The Correlation Between Temporomandibular Disorders and Morphological Occlusion. *Acta Stomatol Croat* 2000;34(1).
4. Mazzetto M.O., Hotta T.H., Pizzo R.C. Measurements of jaw movements and TMJ pain intensity in patients treated with GaAlAs laser. *Braz Dent J* 2010;21:356-60.
5. Venezian G.C., Da Silva M.A., Mazzetto R.G., Mazzetto M.O.. Low level laser effects on pain to palpation and electromyographic activity in TMD patients: A double-blind, randomized, placebo-controlled study. *Cranio* 2010;28:84-91.
6. Katsoulis J., Ausfeld-Hafter B., Windecker-Gétaz I., Katsoulis K., Blagojevic N., Mericske-Stern R. Laser acupuncture for myofascial pain of the masticatory muscles. A controlled pilot study. *Schweiz Monatsschr Zahnmed* 2010;120:213-25.
7. Shirani A.M., Gutknecht N., Taghizadeh M., Mir M. Low-level laser therapy and myofascial pain dysfunction syndrome: A randomized controlled clinical trial. *Lasers Med Sci* 2009;24:715-20.
8. Carrasco T.G., Mazzetto M.O., Mazzetto R.G., Mestriner W. Jr. Low intensity laser therapy in temporomandibular disorder: A phase II double-blind study. *Cranio* 2008;26:274-81.
9. Monici M., Cialdai F., Romano G., Corsetto P.A., Rizzo A.M., Caselli A., Ranaldi F. Effect of IR Laser on Myoblasts: Prospects of Application for Counteracting Microgravity-Induced Muscle Atrophy. *Microgravity Science And Technology* 2012; 25(1):35-42.
10. Shukla D., Muthusekhar M.R. Efficacy of low-level laser therapy in temporomandibular disorders: A systematic review. *Natl J. Maxillofac Surg* 2016;7:62-66.





Guide for Authors

The aim of “Energy for Health” is to spread the results of research on the application of laser and magnetic field in biology and medicine. The journal will publish studies which involve basic research and clinical trials: laser-tissue interaction, effects of laser and electromagnetic field on cells.

Attention will be focused on studies devoted to explain the molecular and cellular mechanisms at the basis of the effects produced by laser and magnetotherapy.

ARTICLE CATEGORIES

Articles are full-length papers presenting complete descriptions of original research, which have not been published and are not being considered for publication elsewhere.

Letters to the editor will be accepted and published if considered pertinent to the aim of the journal by the editorial board.

Reviews are topical overviews on emerging areas of research. They summarize key problems, concepts, experimental approaches, and research opportunities that characterize a subject area. Reviews should not include previously unpublished research results. The Editors generally invite them; authors who wish to submit a review should first consult with the Editors.

Case Reports will be considered if they present data with relevant clinical significance. Case Reports will be accepted if formatted as a research letter with 2 figures maximum, maximum length is up to 1000 words with up to 6 references and 2 tables or figures. There should be no Abstract and no headings.

MANUSCRIPT SUBMISSION

To keep the review time as short as possible, the authors are requested to submit manuscripts (both text and art) in electronic form to the executive editor of “Energy for Health”, Dr. Monica Monici, using the following e-mail address: monica.monici@asalaser.com. Manuscripts submitted via any other method will be returned. The manuscript must be accompanied by a cover letter outlining the significance of the paper. Authors are requested to read carefully the instructions (also available at the web site www.asalaser.com) and to follow them for the preparation of their manuscript.

PREPARATION OF MANUSCRIPTS

Manuscripts must be written in clear, concise, grammatical English. Authors unfamiliar with English usage are encouraged to seek the help of English-speaking persons in preparing their manuscripts. Manuscripts should be double-spaced.

TITLE PAGE

The title page (page 1) should include:

- A concise and informative title (capital bold font; not exceeding 120 characters)
- The name(s) of the author(s) (lower-case bold font, initials in capital letters)
- The affiliation(s) and address(es) of the author(s) (italics font)
- The name of the corresponding author, with complete address, e-mail address, telephone and fax numbers

ABSTRACT

Each paper must be preceded by an abstract (page 2) that summarizes in no more than 250 words a brief introduction, the aim of the study, materials and methods; main results and conclusions. It shouldn't contain any reference.

KEYWORDS

After the abstract, in the same page, a list of 4-6 keywords should be supplied for indexing purposes.

INTRODUCTION

The introduction should describe the state of the art, give a short review of pertinent literature, state the purpose of the investigation. It should be as concise as possible, without subheadings.

MATERIALS AND METHODS

The “materials and methods” section should follow the introduction and should provide enough information to enable the experiments to be reproduced.

Patients (clinical studies): typology of patients (age, sex,...), criteria for enrolment in the study, etc.

Experimental model: cellular, animal, etc.

Instruments: laboratory instruments used for the research.

Methodology: protocols and evaluation mode.

"In the case that laser sources are considered, authors are requested to specify all the necessary technical data pertinent to the experiment(s): laser type and wavelength, emission mode (continuous, pulsed), laser power (peak and average power in case of pulsed emission), laser beam dimensions, beam intensity (Watt/cm² spot area), total energy dose on the irradiated area in a single treatment (J/cm²), duty cycle. In case of laser treatment of cultured cell models, as well as in vivo and ex vivo treatments, authors are requested to specify the dimensions of the treated region, treatment duration and timing modalities (e.g. one session, multiple sessions)."

Data analysis: data-analysis method, statistical analysis.

RESULTS

This section should describe the outcome of the study without any comment. Data should be presented as concisely and clear as possible.

DISCUSSION

The discussion should be an interpretation of the results and their significance, also with reference to works by other authors. The relevance of the results in the research and clinical applications should be explained.

CONCLUSIONS

They should be concise and effective, with reference to possible involvements in the future.

ACKNOWLEDGEMENTS

Concise acknowledgements may be addressed to persons, public and private organizations, companies.

REFERENCES

Reference should be made only to articles that are published or in press. The list of references should only include papers that are cited in the text. They must be progressively numbered (in square brackets) in the order in which they appear in the text and listed at the end of the paper in numerical order. Each reference should cite article title and the authors. Abbreviations of journal titles should follow those used in Index Medicus. References with correct punctuation should be styled as follows:

Reference to a journal publication:

1. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. *Nature*, 2003, 423: 337-342.

Reference to a book:

2. Michaeli W. Extrusion Dies. Hanser Publishers, Munich, Vienna, New York, 1984.

Reference to a chapter in an edited book:

3. Gmünder FK, Cogoli A. Effect of space flight on lymphocyte function and immunity. In: Fregly MJ, Blatteis CM, eds. *Handbook of Physiology*. Oxford:University Press, 1996, vol. 2, pp 799-813.

FIGURES

All figures should be cited in the text and consecutively numbered with arabic numbers. Figures should be exclusively in TIFF or JPG format, with a minimum resolution of 300 dpi. Figure legends must be brief, self-sufficient explanations of the illustrations and double spaced. The legends should be prepared in a separate file in rtf format.

TABLES

All tables should be cited in the text and consecutively numbered with roman numbers.

Each table should have a title and a legend (double spaced) explaining the table content and any abbreviation used. Each table should be prepared in a separate page.

ABBREVIATIONS

Abbreviations should be defined at first mention preceded by the extended name.

COPYRIGHT

The author(s) guarantee(s) that the manuscript is their original work, submitted exclusively to the journal and will not be published elsewhere without the consent of the copyright holders. Upon an article being accepted for publication, the right of publication, as well as rights of translation, of granting reproduction licences, of storage in electronic retrieval systems, of producing special impressions, photocopies, and microcopies are transferred to the publishers.

After manuscript acceptance the corresponding author is responsible for: 1) obtaining from coauthors permission to transfer copyright; 2) obtaining written permission to republish or reproduce all previously published material.

In any case, the journal will be not responsible for the lost of manuscript.

PEER REVIEW

The practice of peer review is to ensure the good quality of the published papers. It is an objective process carried out on all reputable scientific journals. When a manuscript is submitted to “Energy for Health” it is assigned by the Executive Editor to a member of the Editorial Board, based on expertise. If the manuscript is consistent with the aims of the journal, the Editor sends it to colleagues for review, then decides to accept or reject the manuscript on the basis of the referee comments.

WWW.ASACAMPUS.IT



ASAcampus Joint Lab - ASA Research Division and Department of
Experimental and Clinical Biomedical Sciences, University of Florence - Italy